-
Health Canada Put Adderall Back on the Market Based on “Inconclusive Evidence”
Safety of Adderall Cannot be Adequately Evaluated Says Expert Committee Chairman In the October 11, 2005 edition of the Canadian Medical Association Journal ("CMAJ"), an article by Wayne Kondro reveals that Health Canada reintroduced…
-
“Buyer Beware”, Especially If That New Drug Prescribed To You Was Just Approved By The FDA
FDA Approval Does Not Mean A New Drug Won’t Have Any Serious Side Effects In early October 2005, Jonathan D. Rockoff, of The Baltimore Sun, wrote a good article about an important issue for…
-
Controversy Over Safety of Heart Failure Drug Natrecor Continues
Doubting Its Safety, Dr. Eric Topol and Others Want Natrecor Recalled In the October 6, 2005 issue of The New England Journal of Medicine ("NEJM") appears a letter to the editor by Jonathan Sackner-Bernstein,…
-
Toprol: AstraZeneca and FDA Warn of Medication Errors Due to Similarly Named Drugs
"Dear Doctor" Letter About Reports of Patients Receiving Topamax and Tegretol Rather Than Toprol In late September 2005 the FDA and AstraZeneca warned of medication errors and pharmacy mistakes involving three brand-name medications: Toprol,…
-
Cardiac Drug ReoPro: Clinical Trial Is Suspended by Lilly and J&J
Drug Companies Had Been Testing ReoPro for Treatment of Ischemic Strokes On October 5, 2005 it was reported that Eli Lilly & Co. ("Lilly") and Johnson & Johnson ("J&J") have temporarily suspended a late-stage…
-
FDA to Search for Emerging Drug-safety Issues in Health Insurance Company Databases
Public Meeting About Communicating Drug Risks to be Convened in December 2005 In early October 2005 the FDA announced that it has contracted with several large health insurance companies to gain access to their…
